Studies of the Uptake of Tritium Labelled Mepacrine by Tumours
1964

Uptake of Tritium Labelled Mepacrine by Tumours

Sample size: 5 publication Evidence: low

Author Information

Author(s): J. M. Young, F. Wild, I. Simon-Reuss

Primary Institution: University of Cambridge

Hypothesis

Can mepacrine be used as a carrier for tritium to selectively irradiate tumours?

Conclusion

Mepacrine does not show selective uptake in tumours, making it unlikely to be effective for targeted radiation therapy.

Supporting Evidence

  • Normal mepacrine shows limited carcinostatic activity.
  • Previous studies indicated mepacrine could be useful for controlling neoplastic effusions.
  • High concentrations of mepacrine were found in other tissues compared to tumours.
  • Autoradiography showed no uptake of tritium in HeLa cells or Ehrlich ascites tumour cells.
  • Variability in tritium distribution was noted across different tissues.

Takeaway

The study looked at how a special drug called mepacrine behaves in tumours, but it turns out it doesn't go into the tumours as hoped.

Methodology

Rats with Walker 256 carcinoma were injected with tritiated mepacrine, and the distribution of tritium in various tissues was measured over time.

Limitations

The study did not confirm selective uptake of tritium in tumours and showed variability in tissue distribution.

Participant Demographics

Rats bearing Walker 256 carcinoma.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication